Perspective - Journal of Cell Biology and Metabolism (2025) Volume 7, Issue 3

Metabolic Adaptation in Hypoxic Cells: Mechanisms and Implications

Department of Cellular Biology, NovaTech University, Canada.

*Corresponding Author:

Emma Norwood
Department of Cellular Biology
NovaTech University, Canada
E-mail: emma.norwood@biocelllab.org

Received: 03-Jun-2025, Manuscript No. AACBM-25-166661; Editor assigned: 04-Jun-2025, PreQC No. AACBM-25-1666615(PQ); Reviewed: 18-Jun-2025, QC No AACBM-25-1666615; Revised: 21-Jun-2025, Manuscript No. AACBM-25-1666615(R); Published: 28-Jun-2025, DOI:10.35841/aacbm-7.3.266

Citation: Norwood E. Metabolic adaptation in hypoxic cells: Mechanisms and implications. J Cell Biol Metab. 2025;7(3):266.

Introduction

Cells require a constant supply of oxygen to maintain energy production and support essential functions such as proliferation, migration, and differentiation. Oxygen serves as the final electron acceptor in mitochondrial oxidative phosphorylation, the primary process by which cells generate adenosine triphosphate (ATP), the universal energy currency. However, under various physiological and pathological conditions, cells may encounter low oxygen tension, a condition referred to as hypoxia [1]. Hypoxia can result from impaired blood supply, high altitude, rapid tissue growth, or tumorigenesis. Despite the threat posed by oxygen deprivation, many cells have evolved sophisticated mechanisms to adapt their metabolism and survive under hypoxic conditions. These adaptations are critical in developmental biology, tissue repair, ischemic diseases, and cancer progression. Understanding the mechanisms and implications of metabolic adaptation in hypoxic cells offers insights into disease pathophysiology and therapeutic intervention strategies [2].

One of the central features of hypoxic adaptation is a metabolic shift from oxidative phosphorylation to anaerobic glycolysis. Under normal oxygen conditions (normoxia), cells primarily metabolize glucose through glycolysis in the cytoplasm, followed by the tricarboxylic acid (TCA) cycle and oxidative phosphorylation in the mitochondria. This yields approximately 36 ATP molecules per glucose molecule. In hypoxia, however, the reduced availability of oxygen impairs mitochondrial respiration, compelling cells to rely more heavily on glycolysis, which only produces 2 ATP per glucose molecule. To compensate for the diminished ATP yield, hypoxic cells upregulate glucose uptake and enhance glycolytic flux. This process is largely mediated by hypoxia-inducible factors (HIFs), a family of transcription factors that are stabilized and activated in low oxygen environments [3].

Among the HIF family, HIF-1α is the most studied and plays a pivotal role in orchestrating the hypoxic response. Under normoxic conditions, HIF-1α is hydroxylated by prolyl hydroxylase domain (PHD) enzymes, which marks it for recognition and degradation via the von Hippel–Lindau (VHL) E3 ubiquitin ligase complex. In hypoxia, the activity of PHDs is suppressed due to oxygen limitation, allowing HIF-1α to accumulate and translocate to the nucleus [4]. There, it dimerizes with HIF-1β and binds to hypoxia-responsive elements (HREs) in the promoters of target genes. These target genes encode a variety of proteins involved in glucose transport (e.g., GLUT1), glycolytic enzymes (e.g., hexokinase, phosphofructokinase), and lactate production (e.g., lactate dehydrogenase A or LDHA). Consequently, HIF-1α drives a transcriptional program that promotes anaerobic glycolysis, ensuring ATP production continues despite oxygen scarcity [5].

In addition to enhancing glycolysis, hypoxic cells also suppress mitochondrial respiration to minimize the production of reactive oxygen species (ROS), which can accumulate under low oxygen tension and damage cellular components. HIF-1α contributes to this suppression by upregulating pyruvate dehydrogenase kinase 1 (PDK1), which inhibits the activity of pyruvate dehydrogenase (PDH). PDH normally converts pyruvate into acetyl-CoA for entry into the TCA cycle; thus, its inhibition prevents mitochondrial oxidation of pyruvate. This not only limits ROS generation but also ensures that pyruvate is instead converted to lactate and exported out of the cell. Moreover, HIF-1α downregulates the expression of components of the electron transport chain (ETC), such as cytochrome c oxidase (COX) subunits, further reducing mitochondrial oxygen consumption [6].

Interestingly, hypoxia does not uniformly suppress mitochondrial function in all contexts. Some cells, particularly cancer cells, may retain partial mitochondrial activity under hypoxia to support anabolic processes like biosynthesis of lipids and nucleotides. In such cases, metabolic rewiring may involve alternative carbon sources such as glutamine. Glutamine can be converted to α-ketoglutarate and subsequently used in reductive carboxylation pathways to produce citrate for lipid synthesis, even in the absence of robust oxidative metabolism. This metabolic plasticity allows cells to sustain proliferation under adverse conditions [7].

A key consequence of these metabolic adaptations is the alteration of the tumor microenvironment in cancer. Tumor cells often experience chronic hypoxia due to insufficient vascularization. By switching to aerobic glycolysis—a phenomenon known as the Warburg effect—cancer cells increase glucose consumption and lactate production even when oxygen is present. Hypoxia amplifies this effect, reinforcing the metabolic reprogramming that supports rapid tumor growth. The excessive lactate secretion leads to acidification of the tumor microenvironment, which promotes invasion, angiogenesis, and immune evasion. Moreover, hypoxia-induced metabolic changes can impair the function of cytotoxic T cells and natural killer cells, thereby facilitating immune escape. These changes present opportunities for therapeutic intervention, such as targeting HIF-1α, glycolytic enzymes, or lactate transporters to disrupt tumor metabolism and restore immune surveillance [8].

Metabolic adaptation in hypoxia also plays a crucial role in non-cancerous pathologies, such as ischemic heart disease and stroke. In myocardial ischemia, for example, the abrupt loss of oxygen supply triggers a metabolic switch to glycolysis in cardiomyocytes. While this helps sustain ATP production temporarily, prolonged hypoxia leads to acidosis, calcium overload, and eventually cell death. Therapeutic strategies aimed at preconditioning the heart to hypoxia or enhancing glycolytic efficiency are being explored to mitigate ischemic injury. Similarly, in the brain, neurons have limited capacity for anaerobic glycolysis and are highly vulnerable to hypoxic damage. Understanding the metabolic responses of astrocytes and endothelial cells during cerebral ischemia may provide insights into neuroprotection [9].

Beyond pathology, hypoxic adaptation has important physiological roles. During embryonic development, certain tissues experience low oxygen tension as part of the normal maturation process. Stem cells often reside in hypoxic niches that help maintain their pluripotency and self-renewal capacity. HIFs are instrumental in regulating the metabolic profile of stem cells, promoting glycolysis and inhibiting oxidative metabolism to prevent differentiation. Moreover, hypoxia-induced metabolic shifts are critical in wound healing and angiogenesis, where proliferating cells must adapt to fluctuating oxygen availability [10].

Conclusion

In conclusion, metabolic adaptation to hypoxia is a multifaceted process involving coordinated changes in glucose, lipid, amino acid metabolism, and mitochondrial function. These adaptations are orchestrated largely by hypoxia-inducible factors and allow cells to survive, proliferate, or differentiate in oxygen-deficient environments. While beneficial in physiological contexts such as development and regeneration, these adaptations can contribute to disease progression in cancer and ischemic disorders. Continued research into the molecular underpinnings and context-specific responses of hypoxic metabolism holds promise for the development of targeted therapies that exploit metabolic vulnerabilities in disease states.

References

1. Platt MW, Deshpande S. Metabolic adaptation at birth. InSeminars in Fetal and neonatal Medicine 2005 (Vol. 10, No. 4, pp. 341-350). WB Saunders.

Indexed at, Google Scholar, Cross Ref

2. Zeng Z, Liu F, Li S. Metabolic adaptations in pregnancy: a review. Ann Nutr Metab. 2017;70(1):59-65.

Indexed at, Google Scholar, Cross Ref

3. Chouchani ET, Kajimura S. Metabolic adaptation and maladaptation in adipose tissue. Nat Metab. 2019;1(2):189-200.

Indexed at, Google Scholar, Cross Ref

4. Eales KL, Hollinshead KE, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016;5(1):e190-.

Indexed at, Google Scholar, Cross Ref

5. Knox WE, Auerbach VH, Lin EC. Enzymatic and metabolic adaptations in animals. Physiol Rev. 1956;36(2):164-254.

Indexed at, Google Scholar, Cross Ref

6. Chapman NM, Chi H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity. 2022;55(1):14-30.

Indexed at, Google Scholar, Cross Ref

7. Girard J. Metabolic adaptations to change of nutrition at birth. Biol Neonate. 1990;58(Suppl 1):3-15.

Indexed at, Google Scholar, Cross Ref

8. Trexler ET, Smith-Ryan AE, Norton LE. Metabolic adaptation to weight loss: implications for the athlete. J Int Soc Sports Nutr. 2014;11:1-7.

Indexed at, Google Scholar, Cross Ref

9. O'Brien KA, Simonson TS, Murray AJ. Metabolic adaptation to high altitude. Current Opinion in Endocrine and Metabolic Research. 2020;11:33-41.

Indexed at, Google Scholar, Cross Ref

10. Hall KD. Predicting metabolic adaptation, body weight change, and energy intake in humans. American Journal of Physiology-Endocrinology and Metabolism. 2010;298(3):E449-66.

Indexed at, Google Scholar, Cross Ref